サンプル依頼リスト カート
  • English
  • Korean
表紙：脳脊髄液管理の世界市場-2023年～2030年
市場調査レポート
商品コード
1374780

脳脊髄液管理の世界市場-2023年～2030年

Global Cerebrospinal Fluid Management Market -2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 187 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
脳脊髄液管理の世界市場-2023年～2030年
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 187 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

世界の脳脊髄液管理市場は、そのダイナミクスに影響を与える様々な要因によって、長年にわたって大きな成長と変貌を遂げてきました。中枢神経系の恒常性は脳脊髄液（CSF）によって決定的に維持されています。脳脊髄液（CSF）の管理には、シャントや外部ドレナージシステムなどのツールを使用してCSFの流れを維持する必要があります。

特に新興経済諸国では、政府による斬新な製品の発売や研究開発により、先進的な脳脊髄液（CSF）シャントや外部ドレナージ・システムの利用が引き続き促進され、世界の脳脊髄液管理市場が活性化するものと思われます。それぞれの革新的な製品は、さまざまな年齢層の人々に利用される可能性があります。

市場促進要因：市場抑制要因

提携と買収の増加

新興経済諸国は、高額の投資、所得水準、インフラ整備を原動力として、ヘルスケア分野の改善において急速な成長を遂げています。いくつかの国では、研究の高まりにより脳脊髄液管理に対する大きな需要が発生しています。さまざまな国間での共同研究、買収、技術的進歩を伴う製品の発売は、市場の成長を促進する重要な要因です。

2023年6月27日、Spiegelberg GmbH &Co.KG（シュピーゲルベルグ社）は、脳神経外科用の極めて特殊な機器や消耗品を製造する有名な医療機器メーカーで、SHSキャピタルから、脳モニタリングに重点を置くスイスのヘルスケア企業Luciole Medical AGに買収されました。買収後、両社は製品ライン、生産能力、流通網を統合し、それぞれの強みを最大限に発揮することで、最先端の次世代脳モニタリング機器開発のリーダーとして浮上することを目指します。

さらに、2023年6月26日には、画期的な医療技術のアジア市場への導入を加速させることに注力する医療機器メーカーであるLianMedical社と、神経疾患の新しい治療法を開発する臨床段階の医療機器事業者であるCereVasc, Inc.が提携し、CereVasc社のeシャントシステムと関連製品を中国、台湾、香港、マカオの消費者と医療専門家に提供することになりました。

さらに、新しい技術やさまざまなタイプの脳脊髄液管理システムが、治療やさまざまな研究目的で利用されるようになっています。脳脊髄液漏れの増加と革新的な管理製品開発のための研究の増加は、脳脊髄液管理市場の成長を促進する主な要因です。

シャントに伴う合併症

手術手技や抗生物質予防の改善にもかかわらず、感染は依然としてシャントの最も深刻な副作用です。そのため、シャントやEVD用の抗菌性生体材料が開発されています。このようなシャントやEVDを検査室で評価するためには、手術、生体材料、微生物学的な要素を理解することが必要です。

髄液シャント感染症の原因として、ほとんどの場合、皮膚細菌叢に関連した低病原性細菌が挙げられます。シャント感染症の約50％～80％では、コアグラーゼ陰性ブドウ球菌とコアグラーゼ陽性ブドウ球菌が一般的な原因菌であることが示されています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 共同研究や買収の増加
      • 技術的進歩と開発の高まり
    • 抑制要因
      • シャントに伴う合併症
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • SWOT分析
  • 特許分析
  • ロシア・ウクライナ戦争の影響分析
  • DMI意見

第6章 COVID-19分析

第7章 製品タイプ別

  • 脳脊髄液（CSF）シャント
    • 脳室腹膜（VP）シャント
    • 脳室胸膜（VPL）シャント
    • 脳室房室（VA）シャント
  • 体外ドレナージシステム
    • 脳室外ドレナージ（EVD）
    • 腰椎ドレナージ
    • 膀胱ドレナージ

第8章 年齢層別

  • 小児
  • 成人
  • 老人

第9章 エンドユーザー別

  • 病院
  • 外来手術センター
  • 老人医療

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Medtronic
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Integra LifeSciences
  • DePuy Synthes（Johnson & Johnson MedTech）
  • B. Braun SE
  • Natus Medical Incorporated
  • Spiegelberg GmbH & Co. KG
  • Neuromedex GmbH
  • MOLLER Medical GmbH
  • Argi Grup
  • Wellong Instruments Co., Ltd.

第13章 付録

目次
Product Code: MD7185

Overview

The global cerebrospinal fluid management market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. The central nervous system's homeostasis is crucially maintained by cerebrospinal fluid (CSF). The management of cerebral spinal fluid (CSF) entails the use of tools like shunts or external drainage systems to keep the CSF flowing.

Government novel product launch and research, particularly in developing economies, will continue to drive utilization of advanced cerebrospinal fluid (CSF) shunt or external drainage systems and boost the global cerebrospinal fluid management market. The respective innovative products are may be utilized in people with different age groups.

Market Dynamics: Drivers & Restraints

Growing collaborations and acquisitions

Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for cerebrospinal fluid management owing to the rising research. Various collaborations, acquisitions and product launches with technological advanecments among different countries will be a crucial factor driving the growth of the market.

On June 27, 2023, the Spiegelberg GmbH & Co. KG (Spiegelberg), a well-known medical device firm and manufacturer of extremely specialized devices or consumables for neurosurgery, was bought by Luciole Medical AG, a Swiss health care company with a focus on brain monitoring, from SHS Capital. After the acquisition, the businesses will merge their product lines, production capabilities, and distribution networks to maximize their strengths with the goal of emerging as a leader in the development of cutting-edge next-generation brain monitoring devices.

Additionally, on June 26, 2023, LianMedical, a manufacturer of medical devices focused on speeding up the introduction of ground-breaking medical technologies to markets in Asia, and CereVasc, Inc., a clinical-stage medical device business developing new therapies for neurological diseases, joined forces to bring CereVasc's eShunt System along with associated products to consumers and healthcare professionals in China, Taiwan, Hong Kong, and Macau.

Furthermore, the rising utilization of novel technology and different types of cerebrospinal fluid management systems for the treatment or several research purposes. Rising cerebral fluid leak and increasing research for innovative management product development will be a major factor driving the growth of the cerebrospinal fluid management market.

Complications associated with the shunts

Despite improvements in surgical procedures and antibiotic prophylaxis, infection is still the most severe side effect of shunts. As a result, antimicrobial biomaterials for shunts and EVDs have been created. Understanding the surgical, biomaterials, and microbiological components of the issues is necessary for the laboratory assessment of such devices.

Most frequently, some skin flora-associated low-virulence organisms are responsible for CSF shunt infections. In approximately 50% to 80% of the shunt infections, coagulase-negative and coagulase-positive staphylococci were shown to be the common causative agents.

Segment Analysis

The global cerebrospinal fluid management market is segmented based on product type, age group, end user and region.

Cerebrospinal Fluid (CSF) Shunt segment accounted for approximately 56% of market share

Shunts of cerebrospinal fluid are employed to treat hydrocephalus, which is brought on by increased pressure inside the brain. They are meant to be permanent fixtures. External ventricular drainage (EVD), which is utilized for sudden increases in pressure such those brought on by trauma or hemorrhage, is a more transient solution. Patients have CSF shunts implanted to drain fluid from their cysts, ventricles, and subdural deposits to organs that can absorb it, including the peritoneum or atrium.

The most frequent neurosurgical procedure carried out in the US is the insertion of CSF shunts. For existing or probable hydrocephalus/fluid space collections caused by spina bifida or intraventricular hemorrhage, shunts are most frequently implanted in young patients, and they have reduced mortality from these disorders.

On February 10, 2021, the first patient in a study of CereVasc, Inc.'s eShunt System, an investigational device aimed at treating communicating hydrocephalus (CH), which is among the most prevalent neurological conditions in the world, has been treated. CereVasc, Inc. is a clinical-stage medical equipment company creating novel, minimally invasive therapies for neurological diseases. The eShunt device, the first modern minimally invasive procedure for CH, has the potential to provide considerable advantages over the standard of care, a 50-year-old neurosurgical operation marked by frequent failure, an increased risk of infection, and high costs.

Geographical Penetration

North America accounted for around 36% of market share in 2022

Due to the rising need for cerebrospinal fluid management in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for cerebrospinal fluid management.

Increasing expenditure on healthcare and rising research studies, advancement of technologies and different types of products, and increase in biopharmaceutical or medical device business establishment across the region are also contributing to the growth of cerebrospinal fluid management market share of this region. The market in this area is growing as people become more aware of various novel innovative products such as cerebrospinal fluid (csf) shunt. The aforementioned elements further attest to North America's hegemonic position in the world.

North America continues to be a key player in the global cerebrospinal fluid management market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for cerebrospinal fluid management in the U.S. United States have been proactive in executing several initiatives or researches, stimulating cerebrospinal fluid management demand.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global cerebrospinal fluid management market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various device designs, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.

Major medical and biotechnology industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for cerebrospinal fluid management. Now several research studies have been initiated and companies have again started launching novel products with high efficiency. Overall, the impact of the pandemic on the global cerebrospinal fluid management market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for innovative products, like external drainage system.

Key Developments

  • On July 6, 2023, the External Ventricular Drain (EVD) catheter set, Codman Bactiseal is used to treat patients who have hydrocephalus as a side effect of aneurysmal subarachnoid hemorrhage (aSAH), according to positive clinical and financial results stated by Integra LifeSciences Holdings Corporation, an established global medical technology company.
  • On April 8, 2022, the VentrEX Complete is the ideal option for lumbar or ventricular drainage because it includes the VentrEX EVD System with a disposable stand. Its extensive range of intelligent functions, properly labeled parts, and easy-to-read scale ensure simple handling with the highest level of safety.

Competitive Landscape

The major global players in the market include: Medtronic, Integra LifeSciences, DePuy Synthes (Johnson & Johnson MedTech), B. Braun SE, Natus Medical Incorporated, Spiegelberg GmbH & Co. KG, Neuromedex GmbH, MOLLER Medical GmbH, Argi Grup and Wellong Instruments Co., Ltd.

Why Purchase the Report?

  • To visualize the global cerebrospinal fluid management market segmentation based on product type, age group, end user and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of cerebrospinal fluid management market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global cerebrospinal fluid management market report would provide approximately 61 tables, 56 figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Age Group
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing collaborations and acquisitions
      • 4.1.1.2. Rising technological advancements and developments
    • 4.1.2. Restraints
      • 4.1.2.1. Complications associated with the shunts
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. SWOT Analysis
  • 5.6. Patent Analysis
  • 5.7. Russia-Ukraine War Impact Analysis
  • 5.8. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Cerebrospinal Fluid (CSF) Shunt*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Ventriculoperitoneal (VP) Shunt
    • 7.2.4. Ventriculopleural (VPL) Shunt
    • 7.2.5. Ventriculoatrial (VA) Shunt
  • 7.3. External Drainage System
    • 7.3.1. External Ventricular Drainage (EVD)
    • 7.3.2. Lumbar Drainage
    • 7.3.3. Cisternal Drainage

8. By Age Group

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 8.1.2. Market Attractiveness Index, By Age Group
  • 8.2. Pediatric *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Adult
  • 8.4. Geriatric

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Ambulatory Surgical Centers
  • 9.4. Geriatric

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Medtronic*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Integra LifeSciences
  • 12.3. DePuy Synthes (Johnson & Johnson MedTech)
  • 12.4. B. Braun SE
  • 12.5. Natus Medical Incorporated
  • 12.6. Spiegelberg GmbH & Co. KG
  • 12.7. Neuromedex GmbH
  • 12.8. MOLLER Medical GmbH
  • 12.9. Argi Grup
  • 12.10. Wellong Instruments Co., Ltd.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us